Subject(s)
Animals , Male , Mice , Antineoplastic Agents, Alkylating/adverse effects , Cystitis/drug therapy , Hemorrhage/drug therapy , Ifosfamide/adverse effects , /therapeutic use , Cystitis/chemically induced , Cystitis/pathology , Disease Models, Animal , Hemorrhage/chemically induced , Hemorrhage/pathology , Organ SizeSubject(s)
Animals , Male , Mice , Antineoplastic Agents, Alkylating/adverse effects , Cystitis/drug therapy , Hemorrhage/drug therapy , Ifosfamide/adverse effects , /therapeutic use , Cystitis/chemically induced , Cystitis/pathology , Disease Models, Animal , Hemorrhage/chemically induced , Hemorrhage/pathology , Organ SizeABSTRACT
OBJECTIVE: To investigate the possible protective effect of recombinant human interleukin-11 (rhIL-11) against ifosfamide (IFS)-induced hemorrhagic cystitis (HC) MATERIALS AND METHODS: Male Swiss mice (20-30g) were pretreated with rhIL-11 (25-625 mg, subcutaneously.) 30 min before intraperitoneal injection of IFS (400 mg/kg) or with saline (control group). Twelve hours later, HC was evaluated by bladder wet weight (BWW) to quantify edema, Evans blue extravasation (EBE) to measure vascular permeability, and macroscopic and microscopic analysis. All bladders were assessed by histopathological analysis RESULTS: rhIL-11 (at 125 and 625 mg) attenuated the IFS- induced increase of BWW (37.48 percent and 45.44 percent, respectively, p < 0.05) and EBE (62.35 percent and 56.47 percent, respectively, p < 0.05). IFS- induced macroscopic edema and hemorrhage and microscopic alterations, were also prevented by rhIL-11 at 625 mg. (p < 0.05) CONCLUSION: Our results demonstrate a protective effect of rhIL-11 on experimental IFS- induced HC, not previously reported.